Chiome Bioscience Inc. ( (JP:4583) ) has issued an update.
Chiome Bioscience Inc. announced the publication of a research paper in collaboration with Ceinge-Biotecnologie Avanzate, highlighting the effectiveness of their Tribody™ technology in cancer immunotherapy. The study demonstrated that their tri-specific Tribody™ antibody could enhance T cell responses more effectively than existing combination therapies by targeting tumor-associated antigens and immune checkpoint molecules. This advancement suggests significant potential for the Tribody™ technology to improve cancer treatment efficacy, potentially impacting the broader biotech and pharmaceutical sectors by reducing the complexity of cancer therapies for patients.
More about Chiome Bioscience Inc.
Chiome Bioscience Inc. operates in the biotechnology industry, focusing on developing innovative antibody technologies. Their primary product is Tribody™, a multispecific antibody technology designed to target multiple antigens. The company is primarily focused on cancer immunotherapy and aims to develop treatments that simplify therapy by reducing the need for multiple drug combinations.
YTD Price Performance: -7.06%
Average Trading Volume: 12,975,751
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen17.28B
See more insights into 4583 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com